CO5140080A1 - COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES RESPIRATORY DAYS THAT INCLUDE COMBINATIONS OF ANTAGONIS TAS OF NEUROQUININE AND LEUCOTRENE RECEPTORS. - Google Patents

COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES RESPIRATORY DAYS THAT INCLUDE COMBINATIONS OF ANTAGONIS TAS OF NEUROQUININE AND LEUCOTRENE RECEPTORS.

Info

Publication number
CO5140080A1
CO5140080A1 CO99063418A CO99063418A CO5140080A1 CO 5140080 A1 CO5140080 A1 CO 5140080A1 CO 99063418 A CO99063418 A CO 99063418A CO 99063418 A CO99063418 A CO 99063418A CO 5140080 A1 CO5140080 A1 CO 5140080A1
Authority
CO
Colombia
Prior art keywords
neuroquinine
leucotrene
antagonis
tas
receptors
Prior art date
Application number
CO99063418A
Other languages
Spanish (es)
Inventor
Neng-Yang Shih
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO5140080A1 publication Critical patent/CO5140080A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica útil para el tratamiento de la rinitis alérgica, el asma y trastornos relacionados. En una realización, la composición comprende, en combinación, una cantidad terapéuticamente efectiva de al menos un antagonista de neuroquinina, una cantidad efectiva de al menos un inhibidor de 5-lipoxigenasa.<EMI FILE="99063418_1" ID="1" IMF=JPEG >The present invention relates to a pharmaceutical composition useful for the treatment of allergic rhinitis, asthma and related disorders. In one embodiment, the composition comprises, in combination, a therapeutically effective amount of at least one neuroquinine antagonist, an effective amount of at least one 5-lipoxygenase inhibitor. <EMI FILE = "99063418_1" ID = "1" IMF = JPEG>

CO99063418A 1998-10-09 1999-10-06 COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES RESPIRATORY DAYS THAT INCLUDE COMBINATIONS OF ANTAGONIS TAS OF NEUROQUININE AND LEUCOTRENE RECEPTORS. CO5140080A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16960998A 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
CO5140080A1 true CO5140080A1 (en) 2002-03-22

Family

ID=22616408

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99063418A CO5140080A1 (en) 1998-10-09 1999-10-06 COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES RESPIRATORY DAYS THAT INCLUDE COMBINATIONS OF ANTAGONIS TAS OF NEUROQUININE AND LEUCOTRENE RECEPTORS.

Country Status (9)

Country Link
EP (1) EP1119372A1 (en)
JP (1) JP2002527406A (en)
CN (1) CN1329505A (en)
AR (1) AR020741A1 (en)
AU (1) AU6391199A (en)
CA (1) CA2346228A1 (en)
CO (1) CO5140080A1 (en)
PE (1) PE20001095A1 (en)
WO (1) WO2000021564A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091618A1 (en) * 2003-04-15 2004-10-28 Merck Frosst Canada Ltd. Polymorphic form of montelukast sodium
BRPI0513351A (en) * 2004-07-14 2008-05-06 Inflammation Res Ct Company Lt methods for inhibiting tumor metastasis, and inhibiting tumor cell adhesion to endothelial cells and / or inhibiting capillary permeability in the form of transendothelial migration of tumor cells, screening method for a tumor cell capillary permeability inhibitor, and, use of a leukotriene antagonist or a pharmaceutically acceptable salt thereof
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415997D0 (en) * 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
EP2301562B1 (en) * 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
US5696267A (en) * 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
GB9521781D0 (en) * 1995-10-24 1996-01-03 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
JP2002527406A (en) 2002-08-27
CN1329505A (en) 2002-01-02
AR020741A1 (en) 2002-05-29
AU6391199A (en) 2000-05-01
PE20001095A1 (en) 2000-10-31
EP1119372A1 (en) 2001-08-01
CA2346228A1 (en) 2000-04-20
WO2000021564A1 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
BR0307050A (en) Compound, pharmaceutical composition, methods for treating prostaglandin d2 mediated diseases, for treating nasal congestion, for treating allergic asthma, and for treating allergic rhinitis, pharmaceutically acceptable salt, and use of a compound or salt
SE9803710D0 (en) Use of certain drugs for treating nerve root injury
ATE525061T1 (en) SOLID SELF-ADHESIVE COMPOSITIONS FOR THE TOPICAL TREATMENT OF DISORDERS OF THE ORAL MUCOSA
BR0113776A (en) Composition of selected fused pyrrolocarbazoles and method for treating and preventing various diseases using said composition
ATE398983T1 (en) PARTIALLY DEMINERALIZED CORTICAL BONE CONSTRUCTIONS
ATE414519T1 (en) COMBINATION OF AN NMDA ANTAGONIST AND ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER&#39;S DISEASE
BRPI0407993A (en) p38 inhibitors and methods for using them
DE60120372D1 (en) USE OF INSULIN FOR THE TREATMENT OF CORTICAL DISEASES
BR0112756A (en) Compound, pharmaceutical composition, methods for treating prostaglandin-mediated diseases, nasal congestion, allergic asthma, and allergic rhinitis, and use of a compound
BR0316203A (en) Use of an antiallergic agent and a steroid to treat allergic rhinitis
ECSP045520A (en) TREATMENT METHODS WITH PTEC INHIBITORS AND ANTIHIPERTENSIVE AGENTS
PE20020521A1 (en) SUBSTITUTE HETEROCYCLIC COMPOUNDS TO TREAT MULTIPLE DRUG RESISTANCE
CO5160329A1 (en) METHOD FOR PROVIDING INCREASED ABSORPTION OF A PHARMACEUTICALLY ACCEPTABLE AMINA IN THE BLOOD OF A HUMAN AND COMPOSITION THAT INCLUDES A PHARMACEUTICALLY AMINE A NON-STEROID ANTI-INFLAMMATORY PHARMACO
GT199700009AA (en) COMBINED THERAPY FOR OSTEOPOROSIS
BR0211274A (en) Combination of an aldosterone receptor antagonist and an hmg co-reductase inhibitor
BR0316458A (en) Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound
CY1106800T1 (en) METHODS AND COMPOSITIONS USING TEFENADINE METABOLITES IN COMBINATION WITH LEUKOTRIENE INHIBITORS
BR0208405A (en) Cyan-substituted dihydropyrimine compounds and their use to treat disease
CO5140078A1 (en) COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES RESPIRATORY DAYS THAT INCLUDE COMBINATIONS OF ANTAGONIS TAS OF RECEIVERS OF NEUROQUININE AND HISTAMINE
SE9900833D0 (en) Novel combination
BR0214643A (en) Application of an h1 antagonist, and a safe steroid to treat rhinitis
BR0309406A (en) Pharmaceutical composition, preparation process, kit and methods for treating obesity, use of lipase composition and inhibitor, lipase inhibitor and glucomannan or konjac and their use and method of treatment
CO5140080A1 (en) COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES RESPIRATORY DAYS THAT INCLUDE COMBINATIONS OF ANTAGONIS TAS OF NEUROQUININE AND LEUCOTRENE RECEPTORS.
BR0309009A (en) Method for the treatment of mucus hypersecretion
CO5200850A1 (en) PHARMACEUTICAL COMPOSITION FOR PROFILAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH THE FLU, INFLUENZA AND SIMILAR DISEASES AND PROCEDURE FOR APPLICATION